• 1
    Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. Cancer Treat Rev 1985; 12: 4963.
  • 2
    Furie B, Furie BC. Molecular basis of vitamin K-dependent rcarboxylation. Blood 1990; 75: 17531762.
  • 3
    Suttie JW. Synthesis of vitamin K-dependent proteins. FASEB J 1993; 7: 445452.
  • 4
    Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. J Biol Chem 1988; 263: 1103311036.
  • 5
    Levedekou EN, Strohmeyer TG, Effert PJ, Liu ET. Expression of the matrix Gla protein in urogenital malignancies. Int J Cancer 1992; 52: 534537.
  • 6
    Shah DV, Engelke JA, Suttie JW. Abnormal prothrombin in the plasma of rats carrying hepatic tumors. Blood 1987; 69: 850854.
  • 7
    Rick VE. Protein C and protein S: vitamin K-dependent inhibitors of blood coagulation. JAMA 1990; 263: 701703.
  • 8
    Rannels SR, Gallaher KJ, Wallin R, Rannels DE. Vitamin K-dependent carboxylation of pulmonary surfactant-associated proteins. Proc Natl Acad Sci USA 1987; 84: 59525956.
  • 9
    Begleiter A. Cytocidal action of the quinone group and its relationship to antitumor activity. Cancer Res 1983; 43: 481484.
  • 10
    Rotilio G, Mavelli I, Rossi L, Ciriolo MR. Biochemical mechanism of oxidation damage by redox-cycling drugs. Environ Health Perspect 1985; 64: 259264.
  • 11
    Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38: 17451750.
  • 12
    Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharm 1991; 41: 12831292.
  • 13
    Chlebowski RT, Dietrich M, Akman S, Block JB. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 1985; 69: 527532.
  • 14
    Akman SA, Dietrich M, Chlebowski R, Limberg P, Block JB. Modulation of cytotoxicity of menandione sodium bisulfates versus leukemia L1210 by the acid-soluble thiol pool. Cancer Res 1985; 45: 52575262.
  • 15
    Prusad KN, Edwards-Prusad J, Sakamoto A. Vitamin K3 (menodione) inhibits the growth of mammalian tumor cells in culture. Life Sci 1981; 29: 13871392.
  • 16
    Juan C-C, Wu FY-H. Vitamin K3 inhibits growth of human hepatoma Hep G2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem Biophys Res Commun 1993; 190: 907913.
  • 17
    Thor H, Smith MT, Hartzell P, Bellomo G, Jewell SA, Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. J Biol Chem 1982; 257: 1241912425.
  • 18
    Akman SA, Doroshow JH, Dietrich MF, Chlebowski RT, Block JS. Synergistic cytotoxicity between menodione and dicumarol vs. murine leukemia L1210. J Pharmacol Exp Ther 1987; 240: 486491.
  • 19
    Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. Anticancer Res 1992; 12: 16511654.
  • 20
    Gold J. In vivo synergy of vitamin K3 and methotrexate in tumor-bearing animals. Cancer Treat Rep 1986; 70: 14331435.
  • 21
    Noto V, Tapers HS, Jiang Y-H, Janssens J, Bonto J, de Loecker W. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. Cancer 1989; 63: 901906.
  • 22
    Wu FY-H, Liao W-C, Chang H-M. Comparison of antitumor activity of vitamin K1, K2, and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci 1993; 52: 17971804.
  • 23
    Akedo Y, Hosoi T, Inoue S, Ikegami A, Mizuno Y, Kaneki M, Nakamura T, et al. Vitamin K2 modulates proliferation and function of osteoblastic cells in vitro. Biochem Biophys Res Commun 1992; 187: 814820.
  • 24
    Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D, Coleman MS, et al. Des-gamma-carboxy prothrombin as a serium marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 14271431.
  • 25
    Nakao A, Virji MA, Iwaki Y, Carr BI, Iwatsuki S, Starzl TE. Abnormal prothrombin (des-gamma-carboxy-prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 1991; 38: 450453.
  • 26
    Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K, Endoh W, et al. The effects of vitamin K on the generation of des-r-carboxyprothrombin (PIVKA-II) in patients with hepato cellular carcinoma. Am J Gastroenterol 1991; 86: 339345.
  • 27
    Okuda H, Obata H, Nakamishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-r-carboxyprothrombin) by hepatocellular carcinoma. J Hepatol 1987; 4: 357363.
  • 28
    Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-r-carboxyprothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer 1992; 69: 3138.
  • 29
    Carr BI. Complete supression of DCP/PIVKA-2 levels by vitamin K1 administration to patients with hepatocellular carcinoma. Hepatology 1993; 18: 508.
  • 30
    Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI. Growth inhibition by transforming growth factor-beta (TGFβ) type I is restored in TGF β-resistant hepatoma cells after expression of TGFβ receptor type II. Proc Natl Acad Sci USA 1993; 90: 53595363.
  • 31
    Wu FY-H, Chang N-T, Chen W-J, Juan C-C. Vitamin K3-induced cell cycle arrest and apoptostic cell death are accompanied by altered expression of c-fos and c-myc in nasopharyngeal carcinoma cells. Oncogene 1993; 8: 22372244.
  • 32
    Carr BI, Wang Z, Wang M, Finn F. Prothrombin and the vitamin K (VK) cycle: a novel endogenous growth inhibitory pathway. Hepatology 1994; 20: 272a.
  • 33
    Johnson RC, Mack DO, Delancy R, Wolfensberger MR, Esmon C, Price JA, Suen E, et al. “Vitamin K analogues in the study of vitamin K dependent carboxylation.” In: SuttieJW, ed. Vitamin metabolism and vitamin K dependent proteins. Baltimore: University Park Press, 1980: 455466.
  • 34
    Buitenhuis HC, Soute BAM, Vermeer C. Comparison of the vitamins K1, K2, and K3 as cofactors for the hepatic vitamin K-dependent carboxylase. Biochim Biophys Acta 1990; 1034: 170175.
  • 35
    Zucker MB, Siegel M, Cliffton EE, Bellville JW, Howland WS, Grossi CE. The effect of hepatic lobectomy on some blood clotting factors and on fibrinolysis. Ann Surg 1957; 146: 772779.
  • 36
    Hasegawa K, Wang Z, Inagaki M, Carr BI. Characterization of a human hepatoma cell line with acquired resistance to growth inhibition by transforming growth factor beta 1 (TGFβ1). In Vitro 1995; 31: 5561.
  • 37
    Inagaki M, Wang Z, Carr BI. Transforming growth factor beta. 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR-1) in human hepatoma cell lines. Cell Struc Funct 1994; 19: 305313.
  • 38
    Suttie JW, Hageman JM. Vitamin K-dependent carboxylase: de velopment of a peptide substrate. J Biol Chem 1976; 251: 58275830.